NICE nod for Venclyxto in most common leukemia

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending that AbbVie’s Venclyxto (venetoclax) be made available to National Health Service patients in England with difficult-to-treat types of chronic lymphocytic leukemia (CLL) via the Cancer Drugs Fund (CDF), providing conditions of the managed access agreement are followed.

Venetoclax will now be available to patients with CLL, the most common form of leukemia in adults, in the absence of 17p deletion or TP53 mutation who have failed both chemo immunotherapy and a B-cell receptor (BCR) inhibitor.

It has also been recommended for the treatment of adult CLL patients in the presence of 17p deletion or TP53 mutation who are either unsuitable for or have failed a BCR inhibitor.